deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT03164980

QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer (COMPASS)

Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Updated 17 times since 2017 Last updated: Mar 14, 2025 Started: Feb 1, 2018 Primary completion: Aug 8, 2023 Completion: Aug 8, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

A total of 204 patients were planned to be randomized. Due to slow recruitment of the trial, the recruitment was prematurely terminated after randomization of the 89th patient.

A PHASE4 clinical study on Ovarian Cancer and Quality of Life, this trial is terminated or withdrawn. The trial is conducted by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest and has accumulated 17 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jan 2020 · 18 months · monthly snapshot~Jan 2020 – ~Aug 2020 · 7 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~Dec 2023 · 19 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE4

  2. Apr 2025 — Sep 2025 [monthly]

    Terminated PHASE4

    Status: CompletedTerminated

  3. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  5. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE4

    Status: RecruitingCompleted

Show 12 earlier versions
  1. May 2022 — Dec 2023 [monthly]

    Recruiting PHASE4

  2. Sep 2021 — May 2022 [monthly]

    Recruiting PHASE4

  3. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE4

  4. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE4

  5. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE4

  6. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE4

    Phase: NonePHASE4

  7. Jan 2020 — Aug 2020 [monthly]

    Recruiting

  8. Jul 2018 — Jan 2020 [monthly]

    Recruiting

  9. Jun 2018 — Jul 2018 [monthly]

    Recruiting

  10. Apr 2018 — Jun 2018 [monthly]

    Recruiting

    Status: Active Not RecruitingRecruiting · Phase: NANone

  11. Dec 2017 — Apr 2018 [monthly]

    Active Not Recruiting NA

    Status: Not Yet RecruitingActive Not Recruiting

  12. Jun 2017 — Dec 2017 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
  • North Eastern German Society of Gynaecological Oncology
  • PharmaMar
Data source: North Eastern German Society of Gynaecological Oncology

For direct contact, visit the study record on ClinicalTrials.gov .